Cocchiaro Pasquale, De Pasquale Valeria, Della Morte Rossella, Tafuri Simona, Avallone Luigi, Pizard Anne, Moles Anna, Pavone Luigi Michele
Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
Faculty of Medicine, Institut National de la Santé Et de la Recherche Médicale, "Défaillance Cardiaque Aigüe et Chronique", Nancy, France.
Front Cell Dev Biol. 2017 Dec 19;5:114. doi: 10.3389/fcell.2017.00114. eCollection 2017.
Kidney disease is worldwide the 12th leading cause of death affecting 8-16% of the entire population. Kidney disease encompasses acute (short-lasting episode) and chronic (developing over years) pathologies both leading to renal failure. Since specific treatments for acute or chronic kidney disease are limited, more than 2 million people a year require dialysis or kidney transplantation. Several recent evidences identified lysosomal proteases cathepsins as key players in kidney pathophysiology. Cathepsins, originally found in the lysosomes, exert important functions also in the cytosol and nucleus of cells as well as in the extracellular space, thus participating in a wide range of physiological and pathological processes. Based on their catalytic active site residue, the 15 human cathepsins identified up to now are classified in three different families: serine (cathepsins A and G), aspartate (cathepsins D and E), or cysteine (cathepsins B, C, F, H, K, L, O, S, V, X, and W) proteases. Specifically in the kidney, cathepsins B, D, L and S have been shown to regulate extracellular matrix homeostasis, autophagy, apoptosis, glomerular permeability, endothelial function, and inflammation. Dysregulation of their expression/activity has been associated to the onset and progression of kidney disease. This review summarizes most of the recent findings that highlight the critical role of cathepsins in kidney disease development and progression. A better understanding of the signaling pathways governed by cathepsins in kidney physiopathology may yield novel selective biomarkers or therapeutic targets for developing specific treatments against kidney disease.
肾脏疾病是全球第12大死因,影响着8%至16%的总人口。肾脏疾病包括急性(短期发作)和慢性(多年发展)病变,两者都会导致肾衰竭。由于针对急性或慢性肾脏疾病的特定治疗方法有限,每年有超过200万人需要透析或肾脏移植。最近的一些证据表明,溶酶体蛋白酶组织蛋白酶是肾脏病理生理学的关键参与者。组织蛋白酶最初在溶酶体中发现,在细胞的胞质溶胶和细胞核以及细胞外空间也发挥着重要作用,从而参与广泛的生理和病理过程。根据其催化活性位点残基,迄今已鉴定出的15种人类组织蛋白酶分为三个不同的家族:丝氨酸(组织蛋白酶A和G)、天冬氨酸(组织蛋白酶D和E)或半胱氨酸(组织蛋白酶B、C、F、H、K、L、O、S、V、X和W)蛋白酶。具体在肾脏中,组织蛋白酶B、D、L和S已被证明可调节细胞外基质稳态、自噬、凋亡、肾小球通透性、内皮功能和炎症。它们的表达/活性失调与肾脏疾病的发生和进展有关。本综述总结了最近的大部分研究结果,这些结果突出了组织蛋白酶在肾脏疾病发生和进展中的关键作用。更好地了解组织蛋白酶在肾脏生理病理学中所控制的信号通路,可能会产生新的选择性生物标志物或治疗靶点,以开发针对肾脏疾病的特异性治疗方法。